Category CELL THERAPY

PIER MARIA FORNASARI
2023-09-20

The use of cell therapy to treat COVID-19 patients can reduce the risk of death from the disease by 60%, according to a systematic review and meta-analysis conducted by researchers at the University of São Paulo (USP) in Brazil, in partnership with colleagues in Germany and the United States.

Brazilian researchers and collaborators in Germany and the US compiled data from 195 clinical trials conducted in 30 countries between January 2020 and December 2021. The findings are promising, although the authors stress the need for enhanced controls in the making of the products used in cell therapy. Their findings are reported in an article

Read More

No Comments InCELL THERAPY Covid-19
PIER MARIA FORNASARI
2023-04-17

FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older

Read More

No Comments InCELL THERAPY
PIER MARIA FORNASARI
2023-02-28

The Texas Heart Institute Delivers a New First in Heart Failure Treatment Using Cell Therapy

New Cell Therapy Offers Potential Treatment Option for Patients With Chronic Heart Failure Physician-scientists at The Texas Heart Institute announced today the results of the largest cell therapy trial to date in patients with chronic heart failure due to low ejection fraction. The therapy benefited patients by improving the heart’s pumping ability, as measured by

Read More

No Comments InCELL THERAPY
PIER MARIA FORNASARI
2022-06-12

First successful treatment of severe pulmonary hypertension using umbilical cord stem cells

Hannover Medical School doctors successfully treat three-year-old girl / Publication in “Nature Cardiovascular Research“ Clinical researchers at Hannover Medical School (MHH) have succeeded for the first time worldwide in stopping the usually fatal course of the disease in severe pulmonary hypertension thanks to a novel therapeutic approach. A three-year-old girl suffering from so-called pulmonary arterial

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT CELL THERAPY
PIER MARIA FORNASARI
2022-05-14

New type of cell therapy can repair damaged heart tissue after infarction

Researchers at Karolinska Institutet, Technical University of Munich (TUM) in Germany and AstraZeneca, among others, have identified a new type of cell therapy with the potential to heal injuries to the heart after a heart attack. The preclinical study, published in the journal Nature Cell Biology, shows that so-called ventricular progenitor cells can stimulate the heart’s

Read More

No Comments InCELL THERAPY
PIER MARIA FORNASARI
2022-03-12

Cellular therapy improves signs and symptoms of Duchenne muscular dystrophy

Clinical trial results promising for people with the debilitating disorder A clinical trial at UC Davis Health and six other sites showed that a cellular therapy offers promise for patients with late-stage Duchenne muscular dystrophy (DMD), a rare genetic disorder causing muscle loss and physical impairments in young people. The therapy appears to be safe and effective

Read More

No Comments InCELL THERAPY
PIER MARIA FORNASARI
2021-11-09

Ernst & Young white paper details how the Cell Gene Therapy industry can collaborate to advance the field

Harnessing the power of cell and gene therapies will require a next-generation level of collaboration not seen before the COVID-19 pandemic. In brief Before cell and gene therapies can meet increasing demand at the necessary speed and scale, the industry must address key challenges. A fractured supply chain, complicated manufacturing and unprecedented pricing are among

Read More

No Comments InCELL THERAPY
PIER MARIA FORNASARI
2021-11-03

Stem cell treatment failed to reduce inflammation in Multiple Sclerosis

Treatment with mesenchymal stem cells (MSCs) has failed to significantly reduce inflammation in the brain of adults with multiple sclerosis (MS) in a phase 2 clinical trial. The into-the-vein treatment also failed to improve other clinical aspects of the condition. The results were shared in a study titled “Safety, tolerability, and activity of mesenchymal stem cells versus placebo

Read More

No Comments InCELL THERAPY